This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Mohan Palakollu, MD
Advertisement
Dr Palakollu is a first-year psychiatry resident at Creighton University in Omaha, Nebraska.
Articles by Mohan Palakollu, MD
Discover the most effective components of cognitive behavioral therapy for chronic insomnia, enhancing treatment outcomes and patient care strategies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
Dosing MDD Therapies in Medically Complex Patients: Metabolism and Interactions
4
Adjustment Disorder Is Hiding in Plain Sight
5